Effect of p53 gene therapy on the local immunity and the efficacy of patients with nasopharyngeal carcinoma.
- Author:
Yangda QIN
1
;
Jingjin WENG
;
Guiping LAN
;
Haiming WEI
;
Bo HUANG
;
Jinjie SUN
;
Yongfeng SI
Author Information
1. Department of Otolaryngology-Head and Neck Oncology, the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530021, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
CD4-Positive T-Lymphocytes;
immunology;
Carcinoma;
Female;
Genes, p53;
Genetic Therapy;
Humans;
Lymphocyte Count;
Lymphocytes, Tumor-Infiltrating;
immunology;
Male;
Middle Aged;
Nasopharyngeal Carcinoma;
Nasopharyngeal Neoplasms;
immunology;
pathology;
therapy
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2012;26(21):980-983
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the tumor regression and local immune function in nasopharyngeal carcinoma patients treated with p53 gene therapy.
METHOD:The two-step immunohistochemical was done to detect the expression of tumor-infiltrating lymphocytes (TIL) T-cell receptor-CD3, CD4, CD8 and B cell receptor-CD20 in the primary tumor tissue of nasopharyngeal carcinoma. Nasal endoscopy with MRI or CT was used for evaluation of tumor size.
RESULT:The expression of CD3, CD4, CD8 was significantly increased after p53 gene treatment (P < 0.05). There was no significant change in expression of CD20 after p53 gene treatment (P > 0.05). In conventional treatment group, CD3, CD4, CD8 and CD20 (P > 0.05) did not show any significant difference. In gene therapy group at 3 months after treatment, 20 patients had achieved CR, 10 PR, 1 SD, 1 PD. In conventional treatment group, 11 patients had achieved CR, 12 PR,5 SD,3 PD. The response rate between treatment group and control group (CR+PR) was different (P < 0.05). CD3 and CD4 expression was correlated with tumor regression rate (P < 0.05, P < 0.01), and CD8 expression was correlated with the CR rate (P < 0.05).
CONCLUSION:T cells are the most proliferative cell of TII. in NPC patients after p53 gene therapy The local cellular immune status is positively correlated with tumor regression rate.
